Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92. doi: 10.1073/pnas.0806075105. Epub 2008 Sep 25.

PMID:
18818309
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P.

Clin Cancer Res. 2010 May 15;16(10):2861-71. doi: 10.1158/1078-0432.CCR-10-0569. Epub 2010 May 11.

PMID:
20460488
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.

PMID:
19074257
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.

Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34. doi: 10.1073/pnas.0813175106. Epub 2009 Feb 6.

PMID:
19202079
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.

Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S.

J Immunother. 2008 Nov-Dec;31(9):849-57. doi: 10.1097/CJI.0b013e3181891574.

PMID:
18833002
[PubMed - indexed for MEDLINE]
6.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
[PubMed - indexed for MEDLINE]
7.

The CD4+CD25 bright regulatory T cells and CTLA-4 expression in peripheral and decidual lymphocytes are down-regulated in human miscarriage.

Jin LP, Chen QY, Zhang T, Guo PF, Li DJ.

Clin Immunol. 2009 Dec;133(3):402-10. doi: 10.1016/j.clim.2009.08.009. Epub 2009 Sep 18.

PMID:
19766059
[PubMed - indexed for MEDLINE]
8.

CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients.

Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L, Ge Y, Johnson DE, Ju S, Shu Y.

Cell Cycle. 2009 Aug 15;8(16):2578-85. Epub 2009 Aug 19.

PMID:
19597336
[PubMed - indexed for MEDLINE]
Free Article
9.

Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.

Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P.

Cancer Immun. 2008 May 27;8:9.

PMID:
18503261
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

Fu T, He Q, Sharma P.

Cancer Res. 2011 Aug 15;71(16):5445-54. doi: 10.1158/0008-5472.CAN-11-1138. Epub 2011 Jun 27.

PMID:
21708958
[PubMed - indexed for MEDLINE]
Free Article
11.

The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.

Li L, Chao QG, Ping LZ, Xue C, Xia ZY, Qian D, Shi-ang H.

Cancer Biother Radiopharm. 2009 Jun;24(3):357-67. doi: 10.1089/cbr.2008.0612.

PMID:
19538059
[PubMed - indexed for MEDLINE]
12.

Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.

Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, Kuriyama H, Tanaka H, Tanaka J, Yoshizawa H, Nakata K, Gejyo F.

Clin Cancer Res. 2008 Nov 1;14(21):6770-9. doi: 10.1158/1078-0432.CCR-08-1156.

PMID:
18980970
[PubMed - indexed for MEDLINE]
Free Article
13.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. doi: 10.1073/pnas.0712237105. Epub 2008 Feb 19.

PMID:
18287062
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1.

Han Y, Guo Q, Zhang M, Chen Z, Cao X.

J Immunol. 2009 Jan 1;182(1):111-20.

PMID:
19109141
[PubMed - indexed for MEDLINE]
Free Article
15.

Induction of IL-10- and IFN-gamma-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax.

Takatsuka N, Hasegawa A, Takamori A, Shimizu Y, Kato H, Ohashi T, Amagasa T, Masuda T, Kannagi M.

Int Immunol. 2009 Sep;21(9):1089-100. doi: 10.1093/intimm/dxp074. Epub 2009 Aug 4.

PMID:
19654198
[PubMed - indexed for MEDLINE]
Free Article
16.

Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients.

Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, Azuma M, Lee SK, Mizutani S, Morio T.

J Immunol. 2009 May 1;182(9):5515-27. doi: 10.4049/jimmunol.0803256.

PMID:
19380800
[PubMed - indexed for MEDLINE]
Free Article
17.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

PMID:
19001145
[PubMed - indexed for MEDLINE]
Free Article
18.

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A, Ranft A, Dirksen U, Juergens H, Rossig C.

Int J Cancer. 2009 Aug 15;125(4):879-86. doi: 10.1002/ijc.24461.

PMID:
19480009
[PubMed - indexed for MEDLINE]
19.

CLTA-4 blockade in vivo promotes the generation of short-lived effector CD8 T cells and a more persistent central memory CD4 T cell response.

Hokey DA, Yan J, Hirao LA, Dai A, Boyer JD, Jure-Kunkel MN, Weiner DB.

J Med Primatol. 2008 Dec;37 Suppl 2:62-8. doi: 10.1111/j.1600-0684.2008.00324.x.

PMID:
19187432
[PubMed - indexed for MEDLINE]
20.

Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.

Maccalli C, Di Cristanziano V, Fodale V, Corsi D, D'Agostino G, Petrangeli V, Laurenti L, Guida S, Mazzocchi A, Arienti F, Perrone MP, Castelli C, Rivoltini L, Zagonel V, Tartaglia M, Parmiani G, Belardelli F.

Clin Cancer Res. 2008 Nov 15;14(22):7292-303. doi: 10.1158/1078-0432.CCR-08-0832. Epub 2008 Oct 30.

PMID:
18974390
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk